Private Wealth Partners LLC Sells 77,813 Shares of Pfizer Inc. $PFE

Private Wealth Partners LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 13.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 515,346 shares of the biopharmaceutical company’s stock after selling 77,813 shares during the quarter. Pfizer accounts for 1.0% of Private Wealth Partners LLC’s holdings, making the stock its 26th largest holding. Private Wealth Partners LLC’s holdings in Pfizer were worth $12,492,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer in the second quarter valued at approximately $29,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.76 on Tuesday. The firm has a market cap of $140.75 billion, a PE ratio of 13.17, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17. The firm’s fifty day moving average is $24.86 and its 200-day moving average is $24.21.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.